Lates News

Novartis: Etavopivat achieved two co-primary endpoints in the Phase III HIBISCUS trial for sickle cell disease. In the Phase III trial, etavopivat reduced vaso-occlusive crisis events by 27%. Regulatory approval submission for etavopivat is planned for the second half of 2026.